THE EFFECTS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND THEIR METABOLITES ON S-MEPHENYTOIN 4'-HYDROXYLASE ACTIVITY IN HUMAN LIVER-MICROSOMES

被引:81
作者
KOBAYASHI, K
YAMAMOTO, T
CHIBA, K
TANI, M
ISHIZAKI, T
KUROIWA, Y
机构
[1] SHOWA UNIV,SCH PHARMACEUT SCI,DEPT CLIN PHARM,SHINAGAWA KU,TOKYO 142,JAPAN
[2] INT MED CTR JAPAN,RES INST,DEPT CLIN PHARMACOL,TOKYO,JAPAN
[3] INT MED CTR JAPAN,DIV GEN SURG,TOKYO,JAPAN
关键词
S-MEPHENYTOIN 4'-HYDROXYLASE (CYP2C19); CITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; METABOLITES; (NORFLUOXETINE; DEMETHYLCITALOPRAM AND DIDEMETHYLCITALOPRAM);
D O I
10.1111/j.1365-2125.1995.tb05793.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The inhibitory effects of four selective serotonin reuptake inhibitors (SSRIs), fluoxetine, sertraline, paroxetine and citalopram, and three metabolites (norfluoxetine, demethylcitalopram and didemethylcitalopram), on S-mephenytoin 4'-hydroxylation activities in human liver microsomes were studied. The 4'-hydroxylation of S-mephenytoin, a representative substrate toward CYP2C19, was competitively inhibited by all the SSRIs and their metabolites studied. The mean K-i values of fluoxetine, norfluoxetine, sertraline, paroxetine, citalopram, demethylcitalopram and didemethylcitalopram were 5.2, 1.1, 2.0, 7.5, 87.3, 55.8 and 7.7 mu M, respectively. The findings suggest that some SSRIs and their metabolites with a low K-i value (e.g., fluoxetine, norfluoxetine) may reduce the clearance of drugs metabolized by this isoform of P450, thereby resulting in a possible drug-drug interaction, when administered simultaneously. In addition, SSRIs and their metabolites examined herein may be substrates toward CYP2C19.
引用
收藏
页码:481 / 485
页数:5
相关论文
共 33 条
[1]   FLUOXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
HEEL, RC ;
LEWIS, SP .
DRUGS, 1986, 32 (06) :481-508
[2]   THE DEBRISOQUINE HYDROXYLATION TEST PREDICTS STEADY-STATE PLASMA-LEVELS OF DESIPRAMINE [J].
BERTILSSON, L ;
ABERGWISTEDT, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (03) :388-390
[3]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[4]   ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].
BREYERPFAFF, U ;
PFANDL, B ;
NILL, K ;
NUSSER, E ;
MONNEY, C ;
JONZIERPEREY, M ;
BAETTIG, D ;
BAUMANN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358
[5]   EXTREMELY SLOW METABOLISM OF AMITRIPTYLINE BUT NORMAL METABOLISM OF IMIPRAMINE AND DESIPRAMINE IN AN EXTENSIVE METABOLIZER OF SPARTEINE, DEBRISOQUINE, AND MEPHENYTOIN [J].
BROSEN, K ;
GRAM, LF ;
KRAGHSORENSEN, P .
THERAPEUTIC DRUG MONITORING, 1991, 13 (02) :177-182
[6]   STEADY-STATE CONCENTRATIONS OF IMIPRAMINE AND ITS METABOLITES IN RELATION TO THE SPARTEINE DEBRISOQUINE POLYMORPHISM [J].
BROSEN, K ;
KLYSNER, R ;
GRAM, LF ;
OTTON, SV ;
BECH, P ;
BERTILSSON, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (06) :679-684
[7]   THE ROLE OF S-MEPHENYTOIN 4'-HYDROXYLASE IN IMIPRAMINE METABOLISM BY HUMAN LIVER-MICROSOMES - A 2-ENZYME KINETIC-ANALYSIS OF N-DEMETHYLATION AND 2-HYDROXYLATION [J].
CHIBA, K ;
SAITOH, A ;
KOYAMA, E ;
TANI, M ;
HAYASHI, M ;
ISHIZAKI, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (03) :237-242
[8]   DEVELOPMENT AND PRELIMINARY APPLICATION OF A SIMPLE ASSAY OF S-MEPHENYTOIN 4-HYDROXYLASE ACTIVITY IN HUMAN LIVER-MICROSOMES [J].
CHIBA, K ;
MANABE, K ;
KOBAYASHI, K ;
TAKAYAMA, Y ;
TANI, M ;
ISHIZAKI, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (06) :559-562
[9]  
CHIBA K, 1993, J PHARMACOL EXP THER, V266, P52
[10]   THE EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON CYTOCHROME-P4502D6 (CYP2D6) ACTIVITY IN HUMAN LIVER-MICROSOMES [J].
CREWE, HK ;
LENNARD, MS ;
TUCKER, GT ;
WOODS, FR ;
HADDOCK, RE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :262-265